The FDA and the US direct-to-consumer marketplace for stem cell interventions: A temporal analysis

Paul S Knoepfler, Leigh G. Turner

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Hundreds of businesses in the US currently advertise a wide range of non-US FDA-approved stem cell interventions. Here we present a novel systematic temporal analysis of US companies engaged in direct-to-consumer marketing of putative stem cell treatments. Between 2009 and 2014, the number of new US stem cell businesses with websites grew rapidly, at least doubling on average every year. From 2014 to 2016, approximately 90-100 new stem cell business websites appeared per year. In contrast, from 2012 to the present, regulatory activity in the form of FDA warning letters has been limited. These data point to a problematic disconnect between a rapidly expanding US direct-to-consumer stem cell industry and limited FDA oversight of this marketplace. More consistent, timely and effective FDA actions are urgently needed.

Original languageEnglish (US)
Pages (from-to)19-27
Number of pages9
JournalRegenerative Medicine
Volume13
Issue number1
DOIs
StatePublished - Jan 1 2018
Externally publishedYes

Fingerprint

Stem cells
Stem Cells
Industry
Websites
Marketing

Keywords

  • adipose stem cells
  • amniotic stem cells
  • bone marrow stem cells
  • direct-to-consumer advertising
  • FDA
  • patient safety
  • stem cell clinics

ASJC Scopus subject areas

  • Biomedical Engineering
  • Embryology

Cite this

The FDA and the US direct-to-consumer marketplace for stem cell interventions : A temporal analysis. / Knoepfler, Paul S; Turner, Leigh G.

In: Regenerative Medicine, Vol. 13, No. 1, 01.01.2018, p. 19-27.

Research output: Contribution to journalArticle

@article{9ba43617a8834794b1cf6920bd498d02,
title = "The FDA and the US direct-to-consumer marketplace for stem cell interventions: A temporal analysis",
abstract = "Hundreds of businesses in the US currently advertise a wide range of non-US FDA-approved stem cell interventions. Here we present a novel systematic temporal analysis of US companies engaged in direct-to-consumer marketing of putative stem cell treatments. Between 2009 and 2014, the number of new US stem cell businesses with websites grew rapidly, at least doubling on average every year. From 2014 to 2016, approximately 90-100 new stem cell business websites appeared per year. In contrast, from 2012 to the present, regulatory activity in the form of FDA warning letters has been limited. These data point to a problematic disconnect between a rapidly expanding US direct-to-consumer stem cell industry and limited FDA oversight of this marketplace. More consistent, timely and effective FDA actions are urgently needed.",
keywords = "adipose stem cells, amniotic stem cells, bone marrow stem cells, direct-to-consumer advertising, FDA, patient safety, stem cell clinics",
author = "Knoepfler, {Paul S} and Turner, {Leigh G.}",
year = "2018",
month = "1",
day = "1",
doi = "10.2217/rme-2017-0115",
language = "English (US)",
volume = "13",
pages = "19--27",
journal = "Regenerative Medicine",
issn = "1746-0751",
publisher = "Future Medicine Ltd.",
number = "1",

}

TY - JOUR

T1 - The FDA and the US direct-to-consumer marketplace for stem cell interventions

T2 - A temporal analysis

AU - Knoepfler, Paul S

AU - Turner, Leigh G.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Hundreds of businesses in the US currently advertise a wide range of non-US FDA-approved stem cell interventions. Here we present a novel systematic temporal analysis of US companies engaged in direct-to-consumer marketing of putative stem cell treatments. Between 2009 and 2014, the number of new US stem cell businesses with websites grew rapidly, at least doubling on average every year. From 2014 to 2016, approximately 90-100 new stem cell business websites appeared per year. In contrast, from 2012 to the present, regulatory activity in the form of FDA warning letters has been limited. These data point to a problematic disconnect between a rapidly expanding US direct-to-consumer stem cell industry and limited FDA oversight of this marketplace. More consistent, timely and effective FDA actions are urgently needed.

AB - Hundreds of businesses in the US currently advertise a wide range of non-US FDA-approved stem cell interventions. Here we present a novel systematic temporal analysis of US companies engaged in direct-to-consumer marketing of putative stem cell treatments. Between 2009 and 2014, the number of new US stem cell businesses with websites grew rapidly, at least doubling on average every year. From 2014 to 2016, approximately 90-100 new stem cell business websites appeared per year. In contrast, from 2012 to the present, regulatory activity in the form of FDA warning letters has been limited. These data point to a problematic disconnect between a rapidly expanding US direct-to-consumer stem cell industry and limited FDA oversight of this marketplace. More consistent, timely and effective FDA actions are urgently needed.

KW - adipose stem cells

KW - amniotic stem cells

KW - bone marrow stem cells

KW - direct-to-consumer advertising

KW - FDA

KW - patient safety

KW - stem cell clinics

UR - http://www.scopus.com/inward/record.url?scp=85041585043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041585043&partnerID=8YFLogxK

U2 - 10.2217/rme-2017-0115

DO - 10.2217/rme-2017-0115

M3 - Article

C2 - 29327974

AN - SCOPUS:85041585043

VL - 13

SP - 19

EP - 27

JO - Regenerative Medicine

JF - Regenerative Medicine

SN - 1746-0751

IS - 1

ER -